August 2012


Thyroid disease in the perinatal period

Volume 41, No.8, August 2012 Pages 578-581

Simon Forehan


Thyroid hormone plays a critical role in fetal development. In pregnancy, increased thyroid hormone synthesis is required to meet fetal needs, resulting in increased iodine requirements.


This article outlines changes to thyroid physiology and iodine requirements in pregnancy, pregnancy specific reference ranges for thyroid function tests and detection and management of thyroid conditions in pregnancy.


Thyroid dysfunction affects 2–3% of pregnant women. Pregnancy specific reference ranges are required to define thyroid conditions in pregnancy and to guide treatment. Overt maternal hypothyroidism is associated with adverse pregnancy outcomes; thyroxine treatment should be commenced immediately in this condition. Thyroxine treatment has also been shown to be effective for pregnant women with subclinical hypothyroidism who are thyroid peroxidase antibody positive. Gestational thyrotoxicosis needs to be differentiated from Graves disease and rarely requires thionamide treatment. Postpartum thyroiditis most commonly presents with isolated hypothyroidism but a biphasic presentation and isolated hyperthyroidism can occur: a high index of suspicion is warranted for diagnosis.

Thyroid dysfunction affects 2–3% of pregnant women and one in 10 women of childbearing age with normal thyroid function have underlying thyroid autoimmunity, which may indicate reduced functional reserve.1 Up to 18% of women in the first trimester in Australia are thyroid antibody positive.2 Thyroid hormone plays a critical role in pregnancy and understanding the unique changes to thyroid physiology in pregnancy has important implications for the definition and treatment of thyroid disorders in pregnancy.

Thyroid physiology and pregnancy

The fetus is dependent on transplacental transfer of maternal thyroxine (T4). Deiodination of maternal T4 by the fetus results in local fetal production of liothyronine (T3), which is particularly important for neurological development.3,4 Maternal T3 does not cross the placenta and appears to have little, if any, role in development. Other changes in pregnancy include an increase in thyroid binding globulin (TBG), resulting in a larger volume of distribution for thyroid hormone, an increase in urinary iodine excretion and deiodinase activity of the placenta, which increases thyroid hormone metabolism. Pregnancy is therefore a state of increased thyroid hormone demand necessitating an increase in thyroid hormone synthesis by as much as 50%.5,6

Human chorionic gonadotropin (hCG) and thyroid stimulating hormone (TSH) are glycoprotein hormones and share a common alpha subunit; their beta subunits also have significant homology.1 As a result, hCG has thyrotropic activity and as levels increase in pregnancy, there is an appropriate reciprocal decline in TSH.7,8

Thyroid function tests in pregnancy

Several population studies have demonstrated that it is normal for TSH in pregnancy to be below the classic lower limit of normal.9–12 Therefore, use of nonpregnant reference ranges result in the overdiagnosis of hyperthyroid states and under-recognition of hypothyroid states.9 Laboratories should provide trimester specific reference ranges but if these are not available the trimester specific TSH ranges indicated in Table 1 are recommended.13

Free T4 levels tend to increase in the first trimester and then progressively decrease later in pregnancy.10 Free T4 immunoassays generally perform well although should be interpreted with caution as there is significant inter-assay variation and may be influenced by alterations in protein binding kinetics due to pregnancy.12,14

Thyroid stimulating hormone and free T4 are useful to guide diagnosis and monitoring of thyroid conditions in pregnancy. As free T3 does not cross the placenta, ordering of free T3 levels is usually limited to specific circumstances such as T3 predominant thyrotoxicosis (discussed below).

Table 1. Recommended trimester specific reference ranges for TSH13
TrimesterTSH range
First 0.1–2.5 mIU/L
Second 0.2–3.0 mIU/L
Third 0.3–3.0 mIU/L

Iodine requirements

Iodine requirements are increased in pregnancy due to increased thyroid hormone production to maintain maternal euthyroidism and increased urinary iodine excretion. In Australia, Travers et al demonstrated moderate to severe iodine deficiency as indicated by urinary iodine excretion <50 μg/L in 16.6% of pregnant women.15 The World Health Organization recommends 250 μg/day of iodine in pregnancy and lactation to meet the increased demands.16 The National Health and Medical Research Council recommends women who are pregnant have a daily intake of 220 μg iodine and women who are breastfeeding have a daily intake of 270 μg/day.17 Women can obtain some iodine from fortified bread, dairy and seafood; however, an iodine supplement of 150 μg/day is recommended for pregnant women while breastfeeding and for those planning pregnancy to achieve the recommened daily intakes.

While the importance of iodine cannot be understated, excessive iodine can paradoxically cause fetal hypothyroidism and very high doses of iodine should be avoided (eg. Kelp tablets, Lugol's iodine solution).

Overt hypothyroidism

Overt hypothyroidism is defined as an elevated TSH associated with a low free T4 and is clearly associated with adverse pregnancy outcomes. Most notably, Haddow et al demonstrated children born to mothers with untreated overt hypothyroidism had an intelligence quotient (IQ) seven points lower at age 7–9 years compared to children born to euthyroid mothers.18 Obstetric complications of spontaneous miscarriage, premature birth, stillbirth and low birthweight are also described.19,20

Overt maternal hypothyroidism requires urgent treatment with thyroxine. Consideration should be given to loading with thyroxine 150–200 μg/day for 3–4 days in severe cases.5 Liothyronine replacement either alone or in combination should be avoided as overreplacement with T3 may result in maternal hypothyroxinaemia and thus fetal hypothyroidism. Commonly used calcium and iron supplements can reduce thyroxine absorption and should be taken separately.

Women with pre-existing hypothyroidism need to increase their thyroxine dose by approximately 30% in pregnancy – this is best achieved by taking two additional doses per week (in most cases increasing from seven to nine doses per week) on suspicion or confirmation of pregnancy.21 Thyroid stimulating hormone and free T4 should be rechecked in 4 weeks and monitored every 4–6 weeks in the first half of pregnancy and at least once between 26 and 32 weeks gestation, aiming to keep TSH within trimester specific ranges. After delivery, the thyroxine dose can be reduced to prepregnancy levels.13 With adequate treatment during pregnancy, neonatal thyroid function testing is not necessary.

Subclinical hypothyroidism

Subclinical hypothyroidism (SCH) is associated with adverse pregnancy outcomes, particularly miscarriage but not impaired cognitive function.19,20 Benefit of thyroxine treatment has been demonstrated for thyroid peroxidase antibody (TPOab) positive women with SCH, but there is little prospective data on intervention in TPOab negative women.13 Until prospective data are available to guide management, some clinicians may choose to consider low dose thyroxine replacement, which is safe in pregnancy, aiming for TSH values within the trimester specific reference ranges in all women with SCH.

Universal screening versus case finding

Regarding overt hypothyroidism and subclinical hypothyroidism, it is controversial whether universal screening or case finding should be adopted. A recently published study failed to demonstrate neurocognitive benefit of universal screening and intervention compared to selected screening as measured by IQ at 3 years of age.22 It is worth noting that in this trial, thyroxine replacement was commenced on average at 13 weeks 3 days gestation, which is after the critical time for neurodevelopment.22 There remains no prospective data to support universal screening and as such this is not supported by either Royal Australian and New Zealand College of Obstetricians and Gynaecologists or the National Institute for Health and Clinical Excellence guidelines.

Proponents of universal screening argue that screening at the first antenatal visit is commonly practised in some areas, appears cost effective and that case finding misses 30% of cases of thyroid dysfunction.23–25

The American Thyroid Association guidelines do not support universal screening, but recommend ordering TSH at the first antenatal visit for women with high risk attributes for thyroid dysfunction (Table 2), with a reflex free T4 if TSH is abnormal.13 If TSH is elevated the author advocates TPOab testing. In practical terms the American Thyroid Association definition of 'high risk' is broad and likely to capture a large proportion of women. Similarly, consideration should be given to preconception TSH screening in high risk women although this has not been extensively evaluated.

The thyroid antibody positive euthyroid woman

Thyroid antibodies are found in approximately 10% of women, but antenatal antibody screening is not routine.26 Screening for TPOab and TSH is advisable in women with recurrent miscarriage.

Euthyroid antibody positive women have a two–threefold increased risk of spontaneous miscarriage and the risk of preterm birth is approximately doubled.27 Thyroid antibody positivity has also been shown to be a risk factor for perinatal death.28 However, prospective intervention data are limited and the decision to treat with thyroxine or monitor for overt or subclinical hypothyroidism is controversial. In these cases, monitoring of thyroid function every 4 weeks during the first half of pregnancy and once between 26 and 32 weeks gestation has been suggested.13 In the case of recurrent miscarriage, it is acceptable to treat with low dose thyroxine with judicious monitoring of thyroid function as there is potential benefit from this safe treatment.


Overt hyperthyroidism occurs in up to 0.4% of pregnancies, most commonly due to Graves disease and gestational thyrotoxicosis.

Propylthiouracil (PTU) is the treatment of choice in any woman with Graves disease planning pregnancy or in the first trimester as carbimazole is associated with a rare embryopathy. In the second and third trimesters, switching to carbimazole has been suggested due to the risk of fulminant hepatitis with PTU.29–31 However, changing from PTU to carbimazole has the potential to cause fluctuation in thyroid function and the transition can be all the more difficult as the thionamide dose requirement is often decreased from the second trimester. Particularly at the time of transition, TSH and free T4 should be monitored every 2–6 weeks and antithyroid medication adjusted accordingly.

Predominant T3 thyrotoxicosis, commonly seen in patients with toxic nodules and some patients with Graves disease, is a management dilemma. Treatment to normalise T3 may result in hypothyroxinaemia and potentially compromise the fetus. Titration of treatment should be guided by TSH and free T4 and may require an acceptance of some degree of T3 elevation.

In Graves disease, TSH receptor antibodies (TRab) may cross the placenta and cause fetal/neonatal thyrotoxicosis and should be checked at 28–32 weeks gestation. This includes women with a history of Graves disease who have been rendered hypothyroid by either radioiodine or surgery, as TRab may remain elevated in these women. Neonates born to mothers with Graves disease, particularly those with high TRab levels, need to have their thyroid function checked. Regular maternal monitoring postpartum is required as Graves thyrotoxicosis may flare with immune reconstitution. Moderate doses of antithyroid medications (ie. carbimazole 25–30 mg/day or PTU less than 300 mg/day) appear to be safe for the breastfed infant.32 As far as is practical, medication should be taken after breastfeeding. Monitoring of thyroid function in breastfeeding infants of mothers taking antithyroid medications (particularly those taking high doses) should be considered.

Gestational or hCG mediated thyrotoxicosis is usually less severe than Graves thyrotoxicosis. It usually runs a self limited course and rarely requires antithyroid drug treatment.

Table 2. High risk attributes for thyroid dysfunction13
  • A history of thyroid dysfunction or surgery
  • Family history of thyroid disease
  • Goitre
  • Antithyroid antibodies present
  • Symptoms or signs of hypothyroidism
  • Women with type 1 diabetes
  • History of miscarriage or preterm delivery
  • Autoimmune disorder
  • Infertility
  • Prior head or neck irradiation
  • Morbid obesity
  • Age 30 years or older
  • Treatment with amiodarone
  • Treatment with lithium
  • Recent exposure to iodinated contrast

Postpartum thyroiditis

Postpartum thyroiditis (PPT) affects one in 20 women. The majority of women present with isolated hypothyroidism (48%), but a biphasic presentation with hyperthyroidism followed by hypothyroidism (22%) and isolated hyperthyroidism (30%) are also common.33 The nonspecific nature of symptoms warrants a high index of suspicion.

Thyroid antibody positive women are at highest risk (33–50%) of developing PPT. Previous PPT and coincident autoimmune conditions confer higher risk. Permanent hypothyroidism develops in 20–40% of women following PPT and is more likely with higher TSH and/or thyroid antibody levels.33

If hyperthyroidism occurs, onset is usually about 3–6 months postpartum. This needs to be differentiated from Graves disease. The thyrotoxic phase is self limiting – beta blockers can be used for symptomatic thyrotoxicosis but thionamides are not indicated.

If hypothyroidism occurs, onset is usually between six and 12 months postpartum. Thyroxine is initiated for symptomatic hypothyroid women or those trying to conceive. Continuation of thyroxine treatment throughout subsequent pregnancies reduces the risk of inadvertent hypothyroidism but, as a high proportion of women will ultimately recover normal thyroid function, an attempt should be made to wean thyroxine 6–12 months after the final pregnancy. Long term follow up with annual TFT is recommended.

Key points

  • Pregnancy specific reference ranges should be used to guide diagnosis and monitoring of thyroid conditions in pregnancy.
  • The World Health Organization recommends a daily intake of iodine 250 µg during pregnancy and lactation.
  • Hypothyroid states should be treated with thyroxine aiming for a TSH <2.5 prior to conception and in the first trimester and TSH <3.0 for the second and third trimesters.
  • Thyroxine should be increased by two additional doses per week (or 30%) on suspicion or confirmation of pregnancy in women already taking thyroxine.
  • It is important to separate thyroxine intake from preparations that may reduce absorption.
  • Women with high risk attributes for thyroid dysfunction are appropriate for antenatal screening with TSH.
  • Gestational thyrotoxicosis needs to be differentiated from Graves disease and rarely requires thionamide treatment.
  • It is important to maintain a high index of suspicion for postpartum thyroiditis, especially in those with known thyroid antibodies or autoimmune conditions.

Conflict of interest: none declared.


  1. Negro R, Mestman J. Thyroid disease in pregnancy. Best Pract Res Clin Endocrinol Metab 2011;25:927–43.
  2. McElduff A, Morris J. Thyroid function tests and thyroid autoantibodies in an unselected population of women undergoing first trimester screening for aneuploidy. Aust N Z J Obstet Gynaecol 2008;48:478–80.
  3. Burrow G, Fisher D, Larsen P. Maternal and fetal thyroid function. N Engl J Med 1994;331:1072–8.
  4. Bernal J. Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab 2007;3:249–59.
  5. Yassa L, Marqusee E, Fawcett R, et al. Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. J Clin Endocrinol Metab 2010;95:3234–41.
  6. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997;18:404–33.
  7. Glinoer D, De Nayer P, Bourdoux, et al: Regulation of maternal thyroid function during pregnancy. J Clin Endocrinol Metab 1990;71:276.
  8. Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ. Trimester-specific changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine sufficiency. Thyroid 2004;14:1084–90.
  9. Gilbert RM, Hadlow NC, Walsh JP, et al. Assessment of thyroid function during pregnancy: first-trimester (weeks 9-13) reference intervals derived from Western Australian women. Med J Aust 2008;189:250–3.
  10. Stricker R, Echenard M, Eberhart R, et al. Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. Eur J Endocrinol 2007;157:509–14.
  11. Lambert-Messerlian G, McClain M, Haddow JE, et al. First- and secondtrimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study. Am J Obstet Gynecol 2008;199:62.e1
  12. .
  13. Dashe JS, Casey BM, Wells CE, et al. Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. Obstet Gynecol 2005;106:753.
  14. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum. Thyroid 2011;21:1–46.
  15. Anckaert E, Poppe K, Van Uytfanghe K, Schiettecatte J, Foulon W, Thienpont L. FT4 immunoassays may display a pattern during pregnancy similar to the equilibrium dialysis ID-LC/tandem MS candidate reference measurement procedure in spite of susceptibility towards binding protein alterations. Clin Chim Acta 2010;41:1348–53.
  16. Travers C, Guttikonda K, Norton C, et al. Iodine status in pregnant women and their newborns: are our babies at risk of iodine deficiency? Med J Aust 2006;184:617–20.
  17. Andersson M, de Benoist B, Delange F, Zupan J. Prevention and control of iodine deficiency in pregnant and lactating women and in children less than 2-years-old: conclusions and recommendations of the Technical Consultation. Public Health Nutr 2007;10:1606–11.
  18. National Health and Medical Research Council and New Zealand Ministry of Health. Nutrient reference values for Australia and New Zealand including recommended dietary intakes. Canberra: NHMRC, 2006. Available at:
  19. Haddow J, Palomaki G, Allan W, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999;341:549–55.
  20. Krassas G, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010;31:702–55.
  21. Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002;12:63– 8.
  22. Alexander EK, Marqusee E, Lawrence J, et al. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med 2004;351:241–9.
  23. Lazarus J, Bestwick J, Channon S, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med 2012;366:493–501.
  24. Vaidya B, Anthony S, Bilous M, et al. Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding? J Clin Endocrinol Metab 2007;92:203–7.
  25. Chang D, Leung A, Braverman L, Pearce E. Thyroid testing during pregnancy at an academic Boston Area Medical Center. J Clin Endocrinol Metab 2011;96:E1452–6.
  26. Dosiou C, Barnes J, Schwartz A, Negro R, Crapo L, Stagnaro-Green A. Costeffectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. J Clin Endocrinol Metab 2012;97:1536–46.
  27. Hollowell J, Staehling N, Flanders W, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–99.
  28. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Thyroid antibody positivity in the first trimester of pregnancy is associated with negative pregnancy outcomes. J Clin Endocrinol Metab 2011;96:E920–4.
  29. Mannisto T, Vaarasmaki M, Pouta A, et al. Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: a prospective populationbased cohort study. J Clin Endocrinol Metab 2009;94:772–9.
  30. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009;94:1881–2.
  31. Bahn R, Burch H, Cooper D, et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009;19:673–4.
  32. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92:S1–47.
  33. Azizi F, Hedayati M. Thyroid function in breast-fed infants whose mothers take high doses of methimazole. J Endocrinol Invest 2002;25:493–6.
  34. Stagnaro-Green A. Approach to the patient with postpartun thyroiditis. J Clin Endocrinol Metab 2012;97:334–42.


Yes     No

Declaration of competing interests *

Yes No

Additional Author (remove)

Yes No






Competing Interests: 

Your comment is being submitted, please wait

Download citation in RIS format (EndNote, Zotero, RefMan, RefWorks)

Download citation in BIBTEX format (RefMan)

Download citation in REFER format (EndNote, Zotero, RefMan, RefWorks)

For more information see Wikipedia: Comparison of reference management software
Advertisement loading...